Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 2

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 2
---
us, and any free writing prospectus that we have authorized for use in connection with this offering.

TABLE OF CONTENTS

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

| ​                                         | ​ | ​ | EFFECTIVEPER SHAREANDACCOMPANYINGWARRANT(1) |   |     |   | ​ | ​ | EFFECTIVEPER PRE-FUNDEDWARRANT ANDACCOMPANYINGWARRANT(2) |   |     |   | ​ | ​ | TOTAL |   |   |   | ​ |
|:------------------------------------------|:--|:--|:--------------------------------------------|:--|:----|:--|:--|:--|:---------------------------------------------------------|:--|:----|:--|:--|:--|:------|:--|:--|:--|:--|
| Public offering price                     | ​ | ​ | ​                                           | $ |     | ​ | ​ | ​ | ​                                                        | $ |     | ​ | ​ | ​ | ​     | $ |   | ​ | ​ |
| Underwriting discounts and commissions(3) | ​ | ​ | ​                                           | $ |     | ​ | ​ | ​ | ​                                                        | $ |     | ​ | ​ | ​ | ​     | $ |   | ​ | ​ |
| Proceeds to us, before expenses(4)        | ​ | ​ | ​                                           | $ |     | ​ | ​ | ​ | ​                                                        | $ |     | ​ | ​ | ​ | ​     | $ | ​ | ​ | ​ |

(1) Based on a price of $ per set of two shares of common stock and one Common Warrant to purchase one share of common stock and including $ per Common Warrant for each whole accompanying Common Warrant. (2) Based on a price of $ per set of two Pre-Funded Warrants and one Common Warrant to purchase one share of common stock and including $ per Common Warrant for each whole accompanying Common Warrant. (3) Does not include the reimbursement of certain expenses of the underwriter we have agreed to pay. We have also agreed to issue the underwriter or its designees at the closing of this offering warrants to purchase the number of shares of common stock equal to 7% of the aggregate number of shares of common stock and Pre-Funded